KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Accumulated Expenses over the past 16 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly Accumulated Expenses rose 13.53% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 13.53% year-over-year, with the annual reading at $1.0 billion for FY2025, 13.53% up from the prior year.
  • Accumulated Expenses was $1.0 billion for Q4 2025 at Jazz Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $1.1 billion in Q1 2025 and troughed at $374.0 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $781.9 million (2023), against an average of $763.5 million.
  • Biggest five-year swings in Accumulated Expenses: soared 110.21% in 2021 and later fell 1.16% in 2023.
  • Tracing JAZZ's Accumulated Expenses over 5 years: stood at $666.3 million in 2021, then increased by 20.55% to $803.3 million in 2022, then decreased by 1.16% to $793.9 million in 2023, then increased by 14.74% to $910.9 million in 2024, then grew by 13.53% to $1.0 billion in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.0 billion, $1.0 billion, and $874.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.